Theravance Biopharma (NASDAQ:TBPH) Issues Quarterly Earnings Results, Misses Expectations By $0.16 EPS

Theravance Biopharma (NASDAQ:TBPH) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.16), Zacks reports. The company had revenue of $16.87 million for the quarter, compared to analysts’ expectations of $16.11 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. During the same period in the previous year, the business posted ($0.17) earnings per share.

Theravance Biopharma Stock Down 1.1 %

NASDAQ TBPH opened at $9.57 on Friday. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $11.71. The company has a fifty day moving average of $8.36 and a two-hundred day moving average of $8.69.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on TBPH shares. Leerink Partnrs cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. TD Cowen decreased their price objective on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a report on Monday, September 16th. StockNews.com downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Finally, Leerink Partners lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $15.00 to $10.00 in a research report on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $13.75.

Insider Activity

In other news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now owns 322,743 shares of the company’s stock, valued at approximately $2,904,687. This represents a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 6.90% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.